An overview of neuroendocrine tumors and comprehensive insight on the novel targeted therapies that are improving outcomes for patients.
EP. 1: Understanding the Diagnosis and Prognosis of Neuroendocrine Tumors
Diane Reidy-Lagunes, MD, provides an overview of neuroendocrine tumors, along with specific considerations for optimal diagnosis and prognostication.
EP. 2: Neuroendocrine Tumor Pathogenesis and Molecular Testing
Expert insight on the pathogenesis of neuroendocrine tumors and the best use of molecular testing to inform treatment decisions.
EP. 3: An Overview of Treatment Approaches for Neuroendocrine Tumors
Standard treatment pathways for patients with neuroendocrine tumors involving systemic therapy, surgery, and radiation.
EP. 4: Neuroendocrine Tumors: Factors That Inform Therapy Selection
A detailed explanation on how disease and patient factors inform selection from the treatment armamentarium for neuroendocrine tumors.
EP. 5: Systemic Therapy for Advanced Neuroendocrine Tumors
Diane Reidy-Lagunes, MD, outlines goals of therapy and selection of systemic therapy for patients with neuroendocrine tumors.
EP. 6: Advanced Neuroendocrine Tumors: VEGF-Targeted Therapies
Expert reflections on VEGF-targeted therapy’s role in the treatment of patients with neuroendocrine tumors.
EP. 7: Advanced Neuroendocrine Tumors: Clinical Trials With Surufatinib
Considerations for use of surufatinib in patients with neuroendocrine tumors in light of the SANET-p and SANET-ep clinical trials.
EP. 8: Future Directions in the Management of Neuroendocrine Tumors
Looking toward the future management of neuroendocrine tumors, Diane Reidy-Lagunes, MD, shares insight on possible therapy evolutions and ongoing unmet needs.
EP. 9: The Nature of Neuroendocrine Tumors
Expert insight on the subtypes of neuroendocrine tumors and current understanding of the disease microenvironment.
EP. 10: Neuroendocrine Tumors: Options for Initial Therapy
Matthew H. Kulke, MD, provides a broad overview of initial therapy options available for patients with neuroendocrine tumors.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC